

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0085
Inventors: Salceda et al.
Serial No.: 09/664,249
Filing Date: September 18, 2000
Examiner: Not Yet Assigned
Group Art Unit: 1624
Title: A Novel Method of Diagnosing,
Monitoring, Staging, Imaging and
Treating Breast Cancer

I, Jane Massey Licata, Registration No. 32,257, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On this date: February 6, 2001

Jane Massey Licata
Jane Massey Licata, Registration No. 32,257

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into

the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is set forth below; or

() The fee of \$240.00 as set forth in §1.17(p) is attached.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i) (1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously

submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,

Jane Massey Licata

Jane Massey Licata
Registration No. 32,257

Date: February 6, 2001

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. DEX-0085		Serial No. 09/664,249	
				Applicant Salceda et la.			
				Filing Date Sept. 18, 2000		Group 1624	
U. S. PATENT DOCUMENTS							
Examiner		Document	Date	Name	Class	Subclass	
	AA	5,668,267	9-16-97	Watson et al.	536	23.5	
	AB	5,759,776	6-2-98	Smith et al.	435	6	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation YES NO		
	AC	WO 98/18945	7-5-98	PCT	x		
EXAMINER				DATE CONSIDERED			

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. DEX-0085	Serial No. 09/664,249
		Applicant Salceda et al.	
		Filing Date Sept. 18, 2000	Group 1624
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Griffin et al., "Initial Clinical Study of Indium-111-Labeled Clone 110 Anticarcinoembryonic Antigen Antibody in Patients with Colorectal Cancer", <i>J. Clin. Onc.</i> 1991 9:631-640	
	AB	Lauffer, R.B., "Targeted Relaxation Enhancement Agents for MRI*", <i>Magnetic Resonance in Medicine</i> 1991 22:339-342	
	AC	Rosenberg, S. A. et al., "Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 In the Immunotherapy of patients with Metastatic Melanoma", 1988 <i>N. England J. Med.</i> 319:1676-1680	
	AD	Sumerdon et al., "An Optimized Antibody-Chelator Conjugate for Imaging of Carcinoembryonic Antigen with Indium-111", <i>Nucl. Med. Biol.</i> 1990 17:247-254	
EXAMINER		DATE CONSIDERED	